Ministry of science and technology "12th Five Year Plan" national major new drug Danlou tablet creation project officially launched

Song Zhiguo, chairman of Jilin kangnair Pharmaceutical Co., Ltd., introduced at the kick-off meeting that the project will take two years after its launch, and 3200 patients will be used in 66 famous hospitals in the country The safety and effectiveness of Danlou tablet in the treatment of phlegm stasis coronary heart disease will be proved by large sample four stage clinical trial As one of the diseases with the highest morbidity and mortality in the world, coronary heart disease (CHD) causes more than 700000 deaths in China every year, with an increasing trend year by year After the Danlu film project is launched, 600 patients will be tested in the randomized double blind mode to explore the efficacy of Danlou tablets in stabilizing plaque and reduce the incidence rate of myocardial infarction Song said that if the project can achieve the expected results, it will make a great contribution to the health of the Chinese people Incidence rate of China's incidence rate of chronic diseases has been increasing In recent years, China has made great efforts to deepen medical reform Song Zhiguo said that coronary heart disease is preventable and reversible The treatment of phlegm and blood stasis type coronary heart disease with Danlou tablet is to advance the treatment time window, and stable plaque is the best treatment plan for treating coronary heart disease and preventing myocardial infarction The strategic large variety cultivation project of Danlou tablet has been strongly supported by the leaders of the state, the province and the city, and Cornell has invested a lot of money for it Experts from Chinese Academy of Sciences, Chinese Academy of engineering and Chinese Medicine Association attended the kick-off meeting.